Apoptosis-based therapies for hematologic malignancies

被引:320
作者
Reed, JC [1 ]
Pellecchia, M [1 ]
机构
[1] Burnham Inst, La Jolla, CA 92037 USA
关键词
D O I
10.1182/blood-2004-07-2761
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Apoptosis is an intrinsic cell death program that plays critical roles in tissue homeostasis, especially in organs where high rates of daily cell production are offset by rapid cell turnover. The hematopoietic system provides numerous examples attesting to the importance of cell death mechanisms for achieving homeostatic control. Much has been learned about the mechanisms of apoptosis of lymphoid and hematopoietic cells since the seminal observation in 1980 that glucocorticolds induce DNA fragmentation and apoptosis of thymocytes and the demonstration in 1990 that depriving colony-stimulating factors from factor-dependent hematopoietic cells causes programmed cell death. From an understanding of the core components of the apoptosis machinery at the molecular and structural levels, many potential new therapies for leukemia and lymphoma are emerging. In this review, we introduce some of the drug discovery targets thus far identified within the core apoptotic machinery and describe some of the progress to date toward translating our growing knowledge about these targets into new therapies for cancer and leukemia.
引用
收藏
页码:408 / 418
页数:11
相关论文
共 121 条
  • [1] Altieri DC, 1999, LAB INVEST, V79, P1327
  • [2] Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ
    Arnt, CR
    Chiorean, MV
    Heldebrant, MV
    Gores, GJ
    Kaufmann, SH
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (46) : 44236 - 44243
  • [3] Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein
    Aron, JL
    Parthun, MR
    Marcucci, G
    Kitada, S
    Mone, AP
    Davis, ME
    Shen, TS
    Murphy, T
    Wickham, J
    Kanakry, C
    Lucas, DM
    Reed, JC
    Grever, MR
    Byrd, JC
    [J]. BLOOD, 2003, 102 (02) : 652 - 658
  • [4] Safety and antitumor activity of recombinant soluble Apo2 ligand
    Ashkenazi, A
    Pai, RC
    Fong, S
    Leung, S
    Lawrence, DA
    Masters, SA
    Blackie, C
    Chang, L
    McMurtrey, AE
    Hebert, A
    DeForge, L
    Koumenis, IL
    Lewis, D
    Harris, L
    Bussiere, J
    Koeppen, H
    Shahrokh, Z
    Schwall, RH
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (02) : 155 - 162
  • [5] Death receptors: Signaling and modulation
    Ashkenazi, A
    Dixit, VM
    [J]. SCIENCE, 1998, 281 (5381) : 1305 - 1308
  • [6] Signal transduction by tumor necrosis factor and its relatives
    Baud, V
    Karin, M
    [J]. TRENDS IN CELL BIOLOGY, 2001, 11 (09) : 372 - 377
  • [7] The tumor necrosis factor ligand and receptor families
    Bazzoni, F
    Beutler, B
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (26) : 1717 - 1725
  • [8] Rational design and real time, in-cell detection of the proapoptotic activity of a novel compound targeting Bcl-XL
    Becattini, B
    Kitada, S
    Leone, M
    Monosov, E
    Chandler, S
    Zhai, DY
    Kipps, TJ
    Reed, JC
    Pellecchia, M
    [J]. CHEMISTRY & BIOLOGY, 2004, 11 (03): : 389 - 395
  • [9] Mechanisms of caspase activation
    Boatright, KM
    Salvesen, GS
    [J]. CURRENT OPINION IN CELL BIOLOGY, 2003, 15 (06) : 725 - 731
  • [10] Proapoptotic therapy with Oblimersen (bcl-2 antisense oligonucleotide) -: Review of preclinical and clinical results
    Büchele, T
    [J]. ONKOLOGIE, 2003, 26 : 60 - 69